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Abstract 
Background. A number of changes in the management of heart transplantation (HT) patients have each tended to 
reduce the risk of post-HT hematologic cancer, but little information is available concerning the overall effect on 
incidence in the HT population. 
Methods. Comparison of data from the Spanish Post-Heart-Transplantation Tumour Registry for the periods 1991–
2000 and 2001–2010. 
Results. The incidence among patients who underwent HT in the latter period was about half that observed in the 
former, with a particularly marked improvement in regard to incidence more than five yr post-HT. 
Conclusions. Changes in HT patient management have jointly reduced the risk of hematologic cancer in the Spanish 
HT population. Long-term risk appears to have benefited more than short-term risk. 
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Immunosuppression increases the risk of cancer. Among adult heart transplantation (HT) patients, cancers 
cause about 15% of the deaths occurring between one and three yr post-HT, 22–24% of those occurring 
between three and 15 yr post-HT, and about 20% of those occurring thereafter; after five yr, they are the 
main cause of death [1]. In the absence of other causes of death, almost 50% of adult HT patients would 
develop some form of cancer within 15 yr of transplantation [1]. 
Some 10–12% of all post-HT cancers are lymphomatous, with a two-yr post-diagnosis survival rate of 
only about 40% [1, 2]. Most are cases of post-transplant lymphoproliferative disease (PTLD), the 
immediate cause of which has long been known to be, in most cases, infection by Epstein-Barr virus 
(EBV) [3-5]. The risk of EBV-induced PTLD has been reported to be especially acute following the 
induction of immunosuppression by antibodies other than IL2R blockers, at least in the absence of 
effective antiviral prophylaxis [6-8]. 
Over the past decade, HT practice has been changing in regard to both immunosuppression and 
infection. Among the patients recorded in the ISHLT Registry, tacrolimus has to a large extent replaced 
cyclosporine, weaning from prednisone is increasingly common, and the use of azathioprine has 
practically disappeared, while use of mycophenolate mofetil is almost universal [1]. Induction with OKT3 
is a thing of the past (this antibody is no longer marketed), while the use of IL2R blockers is increasing 
[1]. Antiviral prophylaxis and/or CMV viremia monitoring are now commonly considered when 
induction is performed with antithymocyte antibodies (ATG), at least when indicated by donor and 
recipient serology [9]. 
In Spain, around 90% of de novo HT patients now receive induction, about 80% with IL2R blockers 
[10]. Spanish centers have also been prominent in promoting antiviral prophylaxis as a means of 
preventing PTLD. Here, we report the results of a registry study undertaken to determine whether the 
incidence of PTLD and other hematologic cancers among Spanish HT patients exhibits the decreasing 
trend sought by these and other changes in practice.  
Methods 
The Spanish Post-Heart-Transplantation Tumour Registry (SPHTTR) records follow-up data on all 
Spanish HT patients in regard to post-HT neoplasias. In this study, we initially included the records of all 
patients who underwent HT between 1991 and the end of 2010 aged 16 yr or more, and who survived at 
least three months after HT. Fifty-four patients were then excluded because of incomplete records. The 
remaining 4274-member study group (83.2% male, age 52.1 ± 11.0 yr) was divided in two subgroups on 
the basis of the date of HT: 1991–2000 (2299 patients) and 2001–2010 (1975 patients). Follow-up data 
were included up to the end of 2000 for the former subgroup (8804 person-yr), and up to the end of 2010 
for the latter (9696 person-yr). One-yr, five-yr, and overall incidences of hematologic cancer were 
calculated for each of the two period groups, the corresponding between-period relative risks were 
determined, and Kaplan–Meier and cumulative incidence curves were constructed. The Kaplan–Meier 
curves of the two period groups were compared using the log rank test and the cumulative incidence 
curves using Gray's test [11]. 
The two period groups were compared, using chi-square or Fisher's exact tests, in regard to sex, 
distribution in age groups (<45, 45–54, 55–64, and >64 yr), pre-HT smoking, pre-HT neoplasia, initial 
immunosuppression (cyclosporine, MMF, azathioprine, tacrolimus, everolimus, sirolimus), induction 
(OKT3, thymoglobulin, ATG, basiliximab, daclizumab, none), cytolytic induction (any of OKT3, ATG, 
and thymoglobulin vs. any of basiliximab, daclizumab, and none), antiviral prophylaxis with acyclovir or 
ganciclovir in the first three months, and CMV mismatch. Unless prevented by a zero incidence of 
lymphoma, between-period relative risks were calculated for the subgroups listed above using a Poisson 
model, and the desirability of adjusting the overall incidences and risk ratio was evaluated. 
Statistical calculations were performed using Stata 10 or (for Gray's test) R. The institutional review 
board of each participating center approved this research protocol. 
Results 
In all, 44 patients developed hematologic cancer, 30 before and 14 in or after 2001. No patient developed 
a second hematologic cancer during his or her follow-up period in this study, and none of these 44 
patients had suffered a pre-HT neoplasia. Forty cancers were lymphomas and four leukemias. 
The one-yr, five-yr, and overall incidence rates were all lower in the second period than the first 
(Table 1), although only the fall in the overall incidence rate from 3.41 to 1.44 per 1000 person-yr 
(relative risk 0.42) was statistically significant (p = 0.009). In keeping with these trends, the cumulative 
incidence curves (plots of cumulative incidence of hematologic cancer within x years of HT, vs. x) 
differed significantly (p = 0.014), the curve for 2001–2010 lying below the curve for 1991–2000 (Fig. 1). 
The Kaplan–Meier curves (not shown), which also differ significantly (p = 0.007), are very similar to the 
cumulative incidence curves and lie only slightly above them, especially in the case of the period 2001–
2010, for which the Kaplan–Meier and cumulative incidence curves practically coincide. 
Table 1. One- and five-yr incidence of hematologic cancer among Spanish patients undergoing HT in each period, per 1000 person-
yr, together with the whole-group incidences 
 Person-yr Cancers Rate 95% CI RR 95% CI p 
One-yr        
1991–2000 2085.2 10 4.80 2.58–8.91 1.00 – – 
2001–2010 1875.6 4 2.13 0.8–5.68 0.45 0.10–1.54 0.253 
Five-yr        
1991–2000 7076.8 21 2.97 1.93–4.55 1.00 – – 
2001–2010 7336.8 12 1.64 0.93–2.88 0.55 0.25–1.17 0.134 
By period        
1991–2000 8804.1 30 3.41 2.38–4.87 1.00 – – 
2001–2010 9696.3 14 1.44 0.86–2.44 0.42 0.21–0.82 0.009 
        
  
 
 
 
Figure 1. Cumulative incidence of hematologic cancer among Spanish patients undergoing HT in the periods 1991–2000 and 2001–
2010 (p = 0.0143). 
The pre-2001 and post-2000 patient groups differed significantly (p < 0.001) in regard to all the 
variables considered except pre-HT smoking (p = 0.139) (Table 2). In regard to patient characteristics, the 
main differences were an increase in the proportion of female patients; a similar increase in the proportion 
of patients aged ≥65 years, largely at the expense of the 45–64-yr-old group; and an increase in 
transplants with CMV-positive donors and CMV-negative receptors. In regard to treatment variables, 
Table 2 shows the same trends in immunosuppression and induction as were noted above in the 
Introduction (although cyclosporine continued to be used almost twice as often as tacrolimus for initial 
immunosuppression), and there was also an increase in the prophylactic use of antivirals in the first 
three months post-HT. Notably, the prevalence of cytolytic induction fell from 69% to 11% with the 
introduction of IL-2 blockers (which also brought a fall in the number of patients given no induction 
therapy).  
Table 2. Characteristics of Spanish HT patients, 1991–2000, and 2001–2010 
 1991–2000 2001–2010 
p 
 n (%) n (%) 
    
Sex 2299 1975  
Men 1958 (85.2) 1596 (80.8) <0.001 
Women 341 (14.8) 379 (19.2)  
Age group (yr) 2299 1975  
<45 480 (20.9) 407 (20.6) <0.001 
45–54 706 (30.7) 553 (28.0)  
55–64 977 (42.5) 811 (41.1)  
≥65 136 (5.9) 204 (10.3)  
Pre-HT smoker 1874 1726  
No 732 (39.1) 716 (41.5) 0.139 
Yes 1142 (60.9) 1010 (58.5)  
Pre-HT cancer 2299 1975  
No 2264 (98.5) 1919 (97.2) 0.002 
Yes 35 (1.5) 56 (2.8)  
CMV +/− (donor/receptor) 2040 1750  
No 1905 (93.4) 1554 (88.8) <0.001 
Yes 135 (6.6) 196 (11.2)  
Initial immunosuppression 2299 1975  
Cyclosporine 2142 (93.2) 1142 (57.8) <0.001 
Mycophenolate mofetil 371 (16.1) 1557 (78.8) <0.001 
Azathioprine 1850 (80.5) 199 (10.1) <0.001 
Tacrolimus 92 (4.0) 653 (33.1) <0.001 
Everolimus 6 (0.3) 62 (3.1) <0.001 
Sirolimus 8 (0.3) 38 (1.9) <0.001 
Induction 2299 1975  
OKT3 1210 (52.6) 176 (8.9) <0.001 
Daclizumab 1 (0.0) 451 (22.8) <0.001 
None 702 (30.5) 489 (24.8) <0.001 
Cytolytic inductiona 2299 1975  
No 709 (30.8) 1755 (88.9) <0.001 
Yes 1590 (69.2) 220 (11.1)  
Antiviral prophylaxisb 2299 1908  
No 1086 (47.2) 726 (38.1) <0.001 
Yes 1213 (52.8) 1182 (61.9)  
    
 
a OKT3, thymoglobulin or antithymocyte globulin. 
b Acyclovir or ganciclovir in the first three months post-HT. 
Discussion 
The above results show that the incidence of post-HT hematologic cancer was significantly lower in the 
period 2001–2010 than in the preceding decade. This conclusion is supported by analysis of the raw 
incidence data and of cumulative incidence and Kaplan–Meier curves. Although the present study is too 
small to allow more detailed firm inferences concerning a complication that only affects around 5% of 
HT patients, the particularly striking divergence between the two cumulative incidence curves for the 
period more than about five yr post-HT suggests that changes in HT practice may have reduced the risk of 
late development of hematologic cancer rather than that of early development. 
Although this study was conceived largely as a comparison of the pre- and post-IL2R-blocker eras, 
and the SPHTTR records go back to 1984, the two periods compared were both 10 yr long. This was in 
order to minimize between-group differences in the influence of post-HT time on risk. Even so, the two 
groups of patients differed in this respect, because in general the number of heart transplantations per year 
increased during the 1990s and has since then shown a decreasing trend [10]. Note, however, that these 
trends reinforce the conclusion that the risk of hematologic cancer has decreased, as they imply that the 
average follow-up time was longer in the 2001–2010 group than in the 1991–2000 group. 
The similarity of the cumulative incidence curves to the corresponding Kaplan–Meier curves, which 
estimate the trends in intrinsic risk of hematologic cancer (i.e., the risk there would be in the absence of 
other causes of death), suggests that realization of a reduction in intrinsic risk has not been prevented to 
any great extent by death from other causes. The fact that the Kaplan–Meier and cumulative incidence 
curves for 2001–2010 are closer to each other than those for 1991–2000 is consistent with changes in 
practice having delayed death from other causes as well as reducing the risk of hematologic cancer. 
It was not considered appropriate to correct the raw incidence rates and relative risks of Table 1 for 
the effects of any of the variables included in Table 2. Adjustment was generally ruled out by zero 
incidence in one or both periods in one or more of the relevant subgroups; by there being large numbers 
of missing data (pre-HT smoking, CMV status); or by one or more of the strata having very few members 
(e.g., very few patients received sirolimus). Fig. 2 shows the ratio of risk in 2001–2010 to risk in 1991–
2000 for all strata for which this was not the case. Most of the variables in Fig. 2 are not suitable for 
correction of the raw incidences because they may be causally involved in the change in raw incidence 
between the earlier period and the later: this is the case of induction, cytolytic induction, OKT3, 
azathioprine, and antiviral prophylaxis (additionally, for cytolytic induction, OKT3 and azathioprine there 
are rather few members in one of the strata in one of the periods). The remaining variables, sex and age 
group, showed no significant relative risk differences between strata, and correction for these variables 
had little or no effect on overall relative risk, which was still 0.42 when corrected for age group and 0.44 
when corrected for sex. 
 
 
 
Figure 2. Relative risk of hematologic cancer among various subgroups of Spanish HT patients (2001–2010 vs. 1991–2000). Bars 
indicate 95% confidence intervals. Only three age groups are considered, because of zero incidence among patients aged >64 yr in 
the period 2001–2010. 
Although the above reasons rule out the use of the data of Fig. 2 to correct raw incidences, these data 
are not without interest. They show that most of the groups for which it was possible to calculate relative 
risk showed some reduction in risk, although the reduction did not always attain statistical significance. 
This supports the notion that the causes of the reduction in risk between the first period and the second 
were multifactorial. 
The main exception to the trend just noted is the group of patients who received no induction 
treatment: incidence among the 489 who received no induction in 2001–2010 was higher than among the 
702 who received no induction in 1991–2000. However, in the absence of a plausible medical explanation 
of this difference, it seems likely that this increase in observed incidence may actually have been due to 
chance. 
A limitation of the study is that for a number of variables that in principle might be expected to be 
relevant to the incidence of hematologic cancer, it was not possible to compare the two period groups 
because they are not recorded in the SPHTTR. They include donor–receptor EBV mismatch and pre-HT 
risk factors for malignancy other than smoking and malignancy itself. 
In conclusion, in the decade 2001–2010 the incidence of hematologic cancer among patients who 
underwent HT in this period was about half that observed in the period 1991–2000. The reduction appears 
to be particularly marked in regard to long-term incidence. 
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